Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,636,528
  • Shares Outstanding, K 5,952,870
  • Annual Sales, $ 52,546 M
  • Annual Income, $ 21,308 M
  • 36-Month Beta 0.89
  • Price/Sales 4.06
  • Price/Cash Flow 9.55
  • Price/Book 3.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.37 +3.93%
on 05/04/18
37.26 -4.15%
on 04/24/18
-0.91 (-2.48%)
since 04/20/18
3-Month
34.32 +4.08%
on 03/26/18
37.28 -4.18%
on 02/28/18
-0.02 (-0.06%)
since 02/22/18
52-Week
31.67 +12.79%
on 06/08/17
39.43 -9.41%
on 01/29/18
+3.60 (+11.21%)
since 05/22/17

Most Recent Stories

More News
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

JNJ : 122.91 (-0.65%)
GILD : 67.83 (+0.30%)
PFE : 35.72 (-0.22%)
GSK : 40.33 (+0.70%)
Dispute on eye drop size fails to catch Supreme Court's eye

WASHINGTON (AP) — A dispute about the size of eye drops has failed to catch the eye of the Supreme Court.

MRK : 58.45 (-0.20%)
AGN : 154.98 (+0.50%)
PFE : 35.72 (-0.22%)
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

LGND : 187.09 (+0.93%)
ILMN : 270.80 (+0.94%)
ENTA : 100.52 (-1.92%)
PFE : 35.72 (-0.22%)
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

AZN : 37.05 (+0.71%)
JNJ : 122.91 (-0.65%)
LLY : 82.22 (+0.48%)
ZTS : 84.38 (-1.17%)
NVS : 76.84 (+0.07%)
TEVA : 21.00 (-0.43%)
AMGN : 178.36 (+1.07%)
PFE : 35.72 (-0.22%)
GSK : 40.33 (+0.70%)
Dow 30 Stock Roundup: Walmart, Cisco, Home Depot Beat on Earnings

The Dow snapped a record streak of wins to traverse a turbulent week.

AAPL : 187.16 (-0.25%)
CSCO : 43.65 (-0.23%)
JPM : 113.01 (+0.77%)
JNJ : 122.91 (-0.65%)
BRK.B : 198.13 (+0.11%)
HD : 186.87 (-1.54%)
AMGN : 178.36 (+1.07%)
M : 33.12 (-4.31%)
PFE : 35.72 (-0.22%)
GE : 15.29 (+0.20%)
WMT : 83.37 (-1.35%)
Roche Tecentriq Combo Achieves Longer Overall Survival Rate

Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

MRK : 58.45 (-0.20%)
LLY : 82.22 (+0.48%)
RHHBY : 28.1350 (-1.07%)
PFE : 35.72 (-0.22%)
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

EXEL : 21.56 (+3.01%)
RHHBY : 28.1350 (-1.07%)
PFE : 35.72 (-0.22%)
BMY : 52.34 (+0.19%)
LYRICA(R) (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA(R) (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures...

PFE : 35.72 (-0.22%)
Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO

Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society...

PFE : 35.72 (-0.22%)
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

JNJ : 122.91 (-0.65%)
NVS : 76.84 (+0.07%)
AMGN : 178.36 (+1.07%)
PFE : 35.72 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 36.23
1st Resistance Point 35.98
Last Price 35.72
1st Support Level 35.58
2nd Support Level 35.43

See More

52-Week High 39.43
Fibonacci 61.8% 36.47
Last Price 35.72
Fibonacci 50% 35.55
Fibonacci 38.2% 34.63
52-Week Low 31.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar